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Abstract
The present study is the premier clinical attempt to scrutinize the practicability of prophylactic fibrinogen infusion in patients
undergoing heart transplantation (HT). A total of 67 consecutive patients who had undergone HT between January 2012 and
December 2014 were assessed. After exclusion of some patients, 23 patients were given preoperative 2 g fibrinogen concentrate
over a period of 15 minutes after the termination of cardiopulmonary bypass pump and complete reversal of heparin, and 30 patients
were not given. Some laboratories were measured before general anesthesia and at 6 and 24 hours after surgery. In addition, major
adverse events were also evaluated during hospitalization. The mean age of the patients was 39.5+ 11.4 years, with a predominance
of male sex (77.4%). All laboratories at baseline were comparable between groups. The length of hospital stay was longer in
the control group compared to the fibrinogen group (20 [16-22] vs 16 [12-19] days; P¼ .005). There was a trend for patients in the
fibrinogen group to have more acute kidney injury (AKI) after surgery (10% vs 30.4%) and less reoperation for bleeding (20% vs
8.7%). The amount of postoperative bleeding was significantly higher in the control group compared to the fibrinogen group
(P < .001). The number of packed red blood cell transfused during 24 hours after surgery was significantly lower in the fibrinogen
group (P < .001). The transfusion of fibrinogen in patients undergoing HT may be associated with reductions in postoperative
bleeding, the number of packed red blood cells, and hospital length of stay; however, it may enhance postoperative AKI.
Keywords
heart transplantation, fibrinogen, bleeding, transfusion, acute kidney injury
Introduction
It has been proposed that bleeding after heart transplantation
(HT) may be caused by impairment of the coagulation cascades
or technical problems in surgery.1 Patients undergoing HT may
be required to receive blood products due to excessive perio-
perative blood loss. Excess bleeding and subsequent transfu-
sion of blood products increase the possibility of right
ventricular failure, infection, and rejection rate.2 Meanwhile,
it enhances the length of intensive care unit stay, the length of
hospital stay, subsequent renal failure due to right ventricular
failure,3 need to renal replacement therapy,4 and overall
morbidity and mortality.5
In order to assess major bleeding following cardiac surgery,
the platelet dysfunction, coagulation pathway derangements,
and fibrinolysis should be taken into consideration after
excluding the surgical-related issues.6 Fibrinogen has an essen-
tial role in maintaining hemostasis by stabilization of the
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platelet plug and a subsequent clot formation. It has also been
found to be the first factor that dropped to critical low levels in
the major postoperative bleeding.7
For managing the postoperative bleeding conventionally,
fresh frozen plasma (FFP) and cryoprecipitate are used as
the first line of standard replacement,7 but their efficacy in
controlling the bleeding is not clear.6 In addition, it may be
associated with some complications such as overload,
transfusion-related lung injury, and infection.7 Although
plasma-derived fibrinogen concentrate has been used for many
years for patients with congenital fibrinogen deficiency, it has
recently become popular for acquired fibrinogen deficiency,
particularly in cases with bleeding following cardiac surgery.6
In many European countries with the exception of United
Kingdom, the fibrinogen concentrate is a part of standard care
in postoperative cardiac surgery bleeding,7 but its implemen-
tation in managing the postoperative cardiac surgery bleeding
has not been approved in the United States and United King-
dom.7 Some previous studies have shown that the prophylactic
infusion of fibrinogen concentrate reduces the bleeding after
coronary artery bypass surgery and other types of cardiac
surgery.8 To the best of our knowledge, the present study is
the first one to scrutinize the practicability and efficacy of the
prophylactic fibrinogen infusion in patients undergoing HT.
Materials and Methods
Study Protocol and Population
A total of 67 consecutive patients who had undergone HT
from January 2012 to December 2014 in Masih Daneshvari
Hospital, Tehran, Iran, were assessed retrospectively. All
operations were performed by 1 cardiac surgeon, his assis-
tants, and a cardiac anesthetist. This study was approved by
the institutional review board of the National Research Insti-
tute of Tuberculosis and Lung disease (NRITLD) and the
Ethics Committee of Shahid Beheshti University of Medical
Sciences, Tehran, Iran.
The main inclusion criteria included patients older than 18
years undergoing isolated HT. Patients with liver and renal
failure, bleeding propensity, patients on clopidogrel therapy,
patients transferred to intensive care unit on extracorporeal
membrane oxygenation or intra-aortic balloon pump, and
patients who developed surgical bleeding after transplantation
were excluded from the study. All patients in whom the inter-
national normalized ratio (INR) was >1.5 preoperatively and
there was no time for reversal were also excluded from the
study. In addition, in order to evaluate the effect of fibrinogen
on effective clot formation, all patients with postoperative
surgical-related bleeding were excluded.
Surgical Techniques and Interventions
Anesthesia was induced using 10 to 15 mg/kg of intravenous
(IV) fentanyl, 0.2 mg/kg of IV etomidate, and 0.1 mg/kg of IV
pancuronium bromide. Before the commencement of the oper-
ation, a percutaneous central venous line and Swan-Ganz
catheter were placed. Fentanyl, midazolam, and atracurium
were used to maintain general anesthesia. Before cardiopul-
monary bypass (CPB), a baseline activated clotting time (ACT)
was measured, and an IV bolus dose of heparin (400 Units/kg)
was administered to all patients. The next dose of heparin was
targeted at maintaining ACT values above 480 seconds. For
myocardial protection, Belzer UW (Bridge to Life, Europe
Ltd, London, United Kingdom) was used in all cases. The
technique of operation was orthotopic bicaval for all patients.
The same amount of prime solution of the oxygenator was
used in all patients of our cohort, which included 1500 cm3 of
Ringer solution and 100 cm3 of 20% albumin. For all
patients, hypothermia was induced till 32C. Similar fluid
therapy was also used in both the groups. Donors for a spe-
cific recipient was selected from the registry center of the
Iran’s Ministry of Health and acceptance of the transplant
team. Human leukocyte antigen (HLA) typing was not done
for any patient with HT, and all the donors and recipients
were ABO identical or compatible.
In the fibrinogen group, all patients received 2 g of fibrino-
gen (Haemocomplettan P; CSL Behring, Pennsylvania) over a
period of 15 minutes after the termination of CPB and complete
heparin reversal by administration of protamine (1 mg prota-
mine/100 Units heparin) to maintain the ACT below 120 sec-
onds. In controls, all the interventions were same except for not
administering fibrinogen.
Attending cardiac anesthesiologist and cardiac surgeon
decided about all transfusion during early postoperative care.
The amounts of intraoperative and postoperative transfusions
were based on the Society of Thoracic Surgeons guidelines.9
Hematocrit level was maintained between 20% and 30% during
operation. Hematocrit value <25% was considered as transfu-
sion cut point in the intensive care unit. In addition, FFP and
platelets were transfused when INR was >1.5 and platelet count
<100  109/L, respectively.
Laboratory Measurements
Some serum biomarkers were evaluated, including hemoglo-
bin, hematocrit, platelet count, prothrombin time, partial
thromboplastin time, and INR. These values were measured
prior to induction of the general anesthesia and were repeated
at 6 and 24 hours postoperatively. We monitored these para-
meters in relation to the levels of postoperative bleeding.
Outcome Evaluation
The overall chest tube drainage during the first postoperative
day was measured. The amount of transfused packed red blood
cells within first day after surgery was also evaluated. Some
major adverse events were reported during hospitalization,
including cardiovascular events, sepsis, acute kidney injury
(AKI), and death. The diagnosis of AKI was based on the AKI
network criteria,10 and abrupt (within 48 hours) reduction in
renal function as an absolute increase in serum creatinine of 0.3
mg/dL was considered as postoperative AKI.
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Statistical Analysis
Data analysis was performed using SPSS software version 20
(IBM Co, New York). Continuous variables were expressed as
mean + standard deviation or median (interquartile range),
and these values were compared by Student t test or Mann-
Whitney U test, respectively. Nominal variables were
expressed as number (percentage) and were analyzed using
w2 or Fisher exact test. Correlation analysis was used to identify
the correlation between laboratories and the postoperative
bleeding volume. Repeated-measures analysis of variance was
also used to compare continuous variables at different times
between study groups. Statistical significance is considered for
2-tailed values of P < .05.
Result
Of 53 patients who underwent isolated HT, 23 patients were
given human fibrinogen concentrate at the end of operation
and 30 patients were not. The patients’ mean age was 39.5+
11.4 years, and there was no significant difference between
groups (P ¼ .069). Male sex was predominant, and it was
comparable between groups (P ¼ .235). The major cause of
heart failure was dilated cardiomyopathy (84.9%), and one
case had invasive myxoma (1.9%). All laboratories at baseline
were comparable between groups. Other characteristics are
summarized in Table 1.
Intra-aortic balloon pump and extracorporeal membrane
oxygenation were implemented in 2 (3.8%) cases in the control
group and 1 (1.9%) case in the fibrinogen group, respectively
(both P values > .05). The length of stay in hospital was longer
in the control group than that in the fibrinogen group (20 [16-
22] vs 16 [12-19] days; P ¼ .005). Of the in-hospital events
listed in Table 2, there was a trend among patients in fibrinogen
group to have more AKI after surgery (10% vs 30.4%) and less
reoperation for bleeding (20% vs 8.7%). Other postoperative
features are summarized in Table 2.
Based on the correlation analysis, the levels of hemoglobin
and hematocrit at 6 hours were inversely correlated with bleed-
ing volume at 12 hours (r ¼ .408, P ¼ .026 and r ¼ .389, P
¼ .037, respectively). In addition, hemoglobin and hematocrit
at 6 hours correlated with bleeding volume at 24 hours (r ¼
.394, P ¼ .035 and r ¼ .372, P ¼ .047, respectively).
Platelet count at 6 hours and inversely correlated with bleeding
at 24 hours (r ¼ .408, P ¼ .026) and preoperative prothrom-
bin time directly correlated with bleeding at 24 hours (r¼ .316,
P ¼ .047). Other correlations were not significant (not
reported).
When evaluating postoperative changes in laboratories
(from baseline to 24 hours after surgery), there were no signif-
icant differences regarding the between-patient effects (P > .05
for all laboratories; Figure 1). However, the amount of post-
operative bleeding was significantly higher in control
Table 1. Baseline Characteristics and Surgical-Related Factors Based on Study Groups.a
Total Control, n ¼ 30 Fibrinogen, n ¼ 23 P Value
Age, years 39.5 + 11.4 37+ 10.9 42.7 + 11.5 .069
Male 41 (77.4%) 7 (30.4%) 16 (69.6%) .235
BMI, kg/m2 23.1 (20.3-25.1) 22.2 (20.1-24.5) 23.9 (21.8-25.1) .323
Prior histories
Diabetes mellitus 2 (3.8%) 2 (6.7%) 0 (0%) .499
Hypertension 5 (9.4%) 3 (10%) 2 (8.7%) .872
Myocardial infarction 5 (9.4%) 3 (10%) 2 (8.7%) .872
Cerebrovascular events 1 (1.9%) 1 (3.3%) 0 (0%) 1
Smoking 5 (9.4%) 4 (13.3%) 1 (4.3%) .374
Causes of heart failure .083
Dilated CM 45 (84.9%) 28 (93.3%) 17 (73.9%)
Ischemic CM 5 (9.4%) 1 (3.3%) 4 (17.4%)
Restrictive CM 1 (1.9%) 1 (3.3%) 0 (0%)
Others 2 (3.8%) 0 (0%) 2 (8.7%)
Surgical factors
CPB time, minutes 130 (119.5-141) 129 (117-141) 132 (120-144) .478
ACC time, minutes 101 (92-116.5) 97.5 (90-108) 110 (100-129) .019
Anesthesia time, hours 6.1 (5.3-8) 6.2 (5.3-7.1) 6.1 (5.3-9) .353
Baseline laboratories
Hemoglobin, mg/dL 14.1 (2.1) 14.5 (2.7) 13.8 (1.8) .297
Hematocrit, % 41.8 (5.3) 42.1 (5.6) 41.4 (5) .687
Platelet count, 109/L 218.7 (66.5) 214.2 (48) 222.1 (78) .701
PT, seconds 14.1 (3.1) 14.9 (4.1) 13.3 (1.3) .114
PTT, seconds 32 (8.5) 33.5 (9) 30.3 (7.9) .245
Creatinine, mg/dL 1.5 (0.6) 1.5 (0.7) 1.6 (0.5) .562
Abbreviations: BMI, body mass index; CM, cardiomyopathy; CPB, cardiopulmonary bypass; ACC, aortic cross clamp; PT, prothrombin time; PTT, partial
thromboplastin time; SD, standard deviation.
aValues in the table are presented as number (%), mean (SD), or median (interquartile range).
1000 Clinical and Applied Thrombosis/Hemostasis 24(6)
Table 2. Postoperative Features Based on Study Groups.a
Total Control, n ¼ 30 Fibrinogen, n ¼ 23 P Value
IABP after surgery 2 (3.8%) 2 (6.7%) 0 (0%) .207
ECMO after surgery 2 (3.8%) 1 (3.3%) 1 (4.3%) .848
ICU stay, day 4 (3-5) 4 (3-5) 4 (3-5) .647
Hospital stay, day 18 (15-21) 20 (16-22) 16 (12-19) .005
Post-CPB ACT, seconds 130 (120-140) 130 (119-140) 130 (120-140) .684
Packed RBC, number 2 (0-2) 2 (2-3) 0 (0-1) <.001
Reoperation for bleeding 8 (15.1%) 6 (20%) 2 (8.7%) .255
In-hospital events
AKI 10 (18.9%) 3 (10%) 7 (30.4%) .059
Sepsis 2 (3.8%) 2 (6.7%) 0 (0%) .207
Myocardial infarction 0 (0%) 0 (0%) 0 (0%) 1
Cerebrovascular events 0 (0%) 0 (0%) 0 (0%) 1
Death 7 (13.2%) 4 (13.3%) 3 (13%) .975
Abbreviations: IABP, intra-aortic balloon pump; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; CPB, cardiopulmonary bypass; ACT,
anticoagulation clotting time; RBC, red blood cell count; AKI, acute kidney injury.
aValues are presented as number (%) or median (interquartile range).
Figure 1. Changes in laboratories (A) hemoglobin, (B) hematocrit, (C) platelet count, (D) prothrombin time, and (E) partial thromboplastin
time from baseline to 24 hours postoperative time in both groups.
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compared with the fibrinogen group (Figure 2). Furthermore,
the number of packed red blood cells transfused during 24
hours after surgery was significantly lower in patients receiv-
ing fibrinogen compared to the control group (0 [0-1] vs 2 [2-
3] packed cells; P < .001). However, the number of patients
undergoing reoperation for bleeding was comparable between
groups; none of the bleeding etiologies leading to reopera-
tions were surgical related.
When evaluating factors associated with the development of
AKI, patients with postoperative AKI compared to those with-
out AKI had less bleeding at 24 hours (0.8+ 0.45 vs 1.2+ 0.5
L; P ¼ .024) and less number of packed red blood cells trans-
fused (0.8+ 1.1 vs 1.7+ 1.2 number; P¼ .034). The levels of
hemoglobin and hematocrit and the platelet counts were sig-
nificantly lower in patients with AKI compared to those with-
out AKI. In addition, patients with AKI were older (48.7+ 9.1
vs 37.3+ 10.8 years; P ¼ .003), and there was a trend toward
cases with AKI to have longer duration of aortic cross-clamp
time (117.5+ 30.9 vs 105.3+ 17.1 minutes; P ¼ 0.093).
Discussion
In this retrospective and single-center study, we showed for the
first time that the infusion of fibrinogen concentrate after rever-
sal of heparin in HT may be beneficial to reduce the develop-
ment of postoperative bleeding. In addition, the administration
of fibrinogen decreased the hospital length of stay and the
number of packed red blood cells transfused. In addition, there
was a trend among patients receiving fibrinogen to have more
AKI compared to controls.
Perioperative bleeding remained a major complication
following open heart surgeries, owing to the fact that the
excessive postoperative bleeding has been associated with
an increased cost of care and a significant morbidity and
mortality.11,12 The excess transfusion of blood products as the
main management of such events increases the risk of right
ventricular failure2 and decreases patients’ survival.5 About
5% to 10% of patients undergoing HT especially in redo ster-
notomies may have more than 2 L of blood loss at first 24
hours after operation.5 The excessive blood loss may be attrib-
uted to a decline in coagulation factors (ie, hyperfibrinolysis)
and an impaired platelet function.12,13 The use of appropriate
technique for precise evaluation of platelet function, fibrino-
gen levels, and coagulation factors aids physicians in rapid
assessment of the postoperative bleeding events. Moreover, it
helps surgeons to implement optimal treatment such as
administration of pharmacological and/or blood products and
to identify patients requiring further exploration to ameliorate
the morbidity and mortality.
Some of CPB-related factors, including decreases in coagu-
lation factors and platelets, led to hemodilution due to the
prime solution of oxygenator and the activation of fibrinolysis.
Moreover, hypothermia is known as the main causes of the
nonsurgical bleeding after all cardiac surgeries.12,14 However,
in our study, the amount of prime solution in the oxygenator in
all patients was the same (ie, 1000 cm3 of Ringer, 100 cm3 of
Albumin 20%, and 200 cm3 of Mannitol solution 20%).
Hypothermia was induced till 32C for all patients. None of
these factors could interfere with the coagulation pathways in
the study cohort due to the implementation of similar interven-
tions in all patients.
The serum level of fibrinogen may be reduced significantly
during major surgical blood loss. In an animal model of dilu-
tional coagulopathy, even in moderate blood loss, increased
breakdown may be greater than the increase in compensative
fibrinogen synthesis.15 The significance of hypothesis that
patients with higher serum fibrinogen levels experience fewer
bleeding complications further highlights the role of fibrino-
gen in the maintenance of postoperative homeostasis and pre-
vention of excessive bleeding.16,17 Some recent studies have
focused on the role of hyperfibrinolysis as the etiology for
abnormal bleeding after CPB.18 A large study involving 894
patients showed a significant association of hemostatic para-
meters assessment such as platelet count, prothrombin time,
activated partial thromboplastin time, fibrinogen, fibrin
degradation products, ACT, and 16-hour chest tube drainage.
Of these parameters, only postoperative fibrinogen level was
significantly different in bleeders and nonbleeders.19 We did
not measure the fibrinogen level in our patients, and we are
unable to conclude whether our findings are influenced by the
fibrinogen levels.
Karlsson et al found a significant correlation between
plasma fibrinogen level and postoperative bleeding volume,
but no correlation was observed between bleeding and pro-
thrombin time, and a significant inverse correlation was also
demonstrated between bleeding and platelet count in coronary
artery bypass graft surgery.20 Sadeghi et al showed that fibri-
nogen in patients undergoing coronary artery bypass graft
surgery was associated with a significant lower blood loss
(P ¼ .0001) but no significant difference in transfusion of
blood products. Moreover, there were no significant differ-
ences between the control and fibrinogen groups regarding the
preoperative and postoperative laboratories, including pro-
thrombin time, platelet count, hemoglobin, and partial throm-
boplastin time. In addition, postoperative fibrinogen level was
comparable between the groups.21 Moreover, Kindo et al
reported that prothrombin time was an important predictor
Figure 2. The bleeding volume at postoperative day.
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of excess bleeding.22 In lines with some parts of these find-
ings, we found that preoperative prothrombin time and plate-
let counts at 6 hours after surgery were associated with more
postoperative bleeding at 24 hours.
In a study by Ranucci et al,23 the use of fibrinogen concen-
trate decreased postoperative bleeding and blood product trans-
fusions in patients undergoing complex cardiac surgery. In
contrast, patients who underwent high-risk cardiac surgeries
with intraoperative bleeding (blood volume between 60 and
250 mL suctioned from the thoracic cavity in a period of 5
minutes) were given either fibrinogen concentrate or nothing.
They found that there was no significant difference in the
amount of intraoperative blood loss and more rates of postopera-
tive cardiovascular events in fibrinogen group.24 In addition, in
the latest meta-analysis up to the end of 2016, it was concluded,
the use of fibrinogen significantly reduced the bleeding volume
(mean difference 127 mL; P ¼ .002; I2 ¼ 54%) and the num-
ber of packed red blood cell units (mean difference 0.9; P <
.001; I2 ¼ 42%). None of the meta-analyzed studies was pow-
ered to estimate the survival and adverse events, but the rate of
mortality was lower in the fibrinogen group.25 It seems that
further large-scale trials are required to have a more robust con-
clusion regarding the beneficial effect of perioperative fibrino-
gen in the setting of cardiac surgery.
Two main factors may impact the effect of fibrinogen,
including fibrinogen level and fibrinogen dose. Based on a
pooled correlation coefficient in a meta-analysis, it has been
found that there was weak to moderate correlations between
preoperative (0.40) and postoperative (0.23) fibrinogen lev-
els and postoperative bleeding.26 In contrast, some studies
showed no association between preoperative fibrinogen level
and postoperative bleeding.27 However, the latest trial has
shown that the fibrinogen level increased in both groups (fibri-
nogen and control groups) at 24 hours, which can be explained
by the increased fibrinogen production by liver on postopera-
tive day. It should be mentioned that fibrinogen concentration
has a dose-dependent effect on platelet aggregation, clot for-
mation, and maintaining hemostatic process.24Rahe-Meyer
et al28 infused 8 g fibrinogen concentrate with a guide of throm-
boelastometry which results in the cessation of intraoperative
bleeding during thoracoabdominal aortic aneurysm surgery and
reduced transfusion and 24-hour drainage volume. However, in
the majority of previous studies, the fibrinogen dose has been 2
to 4 g.24,25 It has been found that the fibrinogen level of 2.2 g/L
was the best cutoff point to predict bleeding.22 On the other
hand, in the latest trial, the targeted level to achieve a postinfu-
sion plasma fibrinogen level was 2.5 g/L, which did not result
in the reduction of bleeding and blood product transfusion.24 It
may be assumed that small doses of fibrinogen have attenuated
effects on controlling nonsurgical bleeding, while with higher
doses its impact became augmented.
Of main concern in postoperative care of patients under-
going cardiac surgeries is AKI. None of the previous studies
have reported the effect of fibrinogen on postoperative AKI in
patients undergoing cardiac surgeries except for 2 studies in
which there was no difference between patients receiving
fibrinogen and comparator with regard to the development of
AKI requiring dialysis 29 and renal insufficiency or failure.24 A
study has shown that higher fibrinogen level was associated
with higher contrast-induced AKI in patients undergoing cor-
onary intervention.30 Fibrinogen is significantly upregulated in
the kidney after development of AKI.31 Moreover, in a study of
patients with AKI, fibrinogen deposition was observed in the
glomerular basement membrane, leading to the reduction in
glomerular filtration was found.32 Our finding regarding AKI
may be caused by the higher level of fibrinogen in patients
receiving fibrinogen. Moreover, we found that cases with AKI
had less bleeding and therefore received less transfusion, which
support the hypothesis mentioned here.
Some limitations to our study should be considered. Firstly,
it is a small retrospective study. Secondly, the lack of perio-
perative thromboelastometric monitoring and measurement of
fibrinogen level preclude us to correlate our findings with coa-
gulation status and patients’ outcomes.
Conclusion
The transfusion of preoperative fibrinogen concentrate in
patients undergoing HT may be associated with reductions in
postoperative bleeding volume at 24 hours, the number of
packed red blood cells transfused at 24 hours, and hospital
length of stay; however, it may lead to enhancement of post-
operative AKI.
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